Soligenix, Inc. (SNGX) AI Stock Analysis

Soligenix, Inc. is a biopharmaceutical company dedicated to developing and commercializing treatments for rare diseases in the United States. The company operates two segments: Specialized BioTherapeutics and Public Health Solutions. Its Specialized BioTherapeutics segment advances SGX301 (HyBryte) for cutaneous T-cell lymphoma, SGX942 for oral mucositis in head and neck cancer patients, SGX203 for pediatric Crohn's disease, and SGX302 for mild-to-moderate psoriasis. Its Public Health Solutions segment develops RiVax, a ricin toxin vaccine candidate, along with SGX943 for emerging infectious diseases, ThermoVax for stabilizing vaccines, and CiVax for COVID-19 prevention.

Soligenix generated revenue of $1.9M in FY2020 before dropping to $33,351 in FY2021. Revenue rebounded to $250,000 in FY2022 and reached $839,359 in FY2023, but declined 85.8% to $119,371 in FY2024. Over the 5-year period from FY2019 to FY2024, revenue recorded a CAGR of -48.2%. The company incurred persistent net losses, posting -$17.7M in FY2020, -$12.6M in FY2021, -$13.8M in FY2022, -$6.1M in FY2023, and -$8.3M in FY2024. For the latest quarter ended June 30, 2026, quarterly revenue growth fell 100.0% year-over-year, leaving trailing twelve month revenue at $0 and EPS at -$0.79.

As of June 30, 2026, Soligenix held $9.8M in cash and short-term investments against total debt of $302,589, resulting in net cash of $9.5M. The company maintains total assets of $10.5M and shareholders' equity of $6.6M, yielding a current ratio of 2.77 and a debt-to-equity ratio of 0.05. Operating cash flow in FY2024 stood at -$8.4M, with free cash flow at -$8.4M. Capital expenditures for FY2025 totaled $5,883, while the share count expanded 8826.6% over 5 years.

Soligenix carries a market capitalization of $7.7M and an enterprise value of -$1.2M. The stock trades at a forward P/E of 12.3x, compared to the median of 17.3x for its US-listed Healthcare peers. Its price-to-sales multiple is 9.8x, exceeding the US-listed Healthcare peer median of 4.1x, while its price-to-book ratio sits at 1.2x. Over the past year, the stock declined 77.4%, trailing the S&P 500 return of 16.8%, and fell 99.9% over five years versus an 83.0% gain for the benchmark index.

Soligenix has 1 analyst rating, categorized as a Strong Buy, with 0 Buy, Hold, Sell, or Strong Sell ratings. The mean price target is $1.38, representing potential upside of 292.9% from the last close of $0.35 on October 16, 2026. For the current fiscal year ending December 31, 2026, consensus estimates project an EPS of -$0.40 and revenue of $0. Soligenix has beaten EPS estimates in 3 of the last 4 quarters, and its next earnings date is November 6, 2026.

This page is an AI-written research summary of Soligenix, Inc. (SNGX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: SNGX income statement, SNGX balance sheet, SNGX key metrics, SNGX analyst forecast, SNGX chart. See the SNGX stock overview for the latest quote and news.